2023
Omission of Radiotherapy After Breast-Conserving Surgery for Women With Breast Cancer With Low Clinical and Genomic Risk: 5-Year Outcomes of IDEA
Jagsi R, Griffith K, Harris E, Wright J, Recht A, Taghian A, Lee L, Moran M, Small W, Johnstone C, Rahimi A, Freedman G, Muzaffar M, Haffty B, Horst K, Powell S, Sharp J, Sabel M, Schott A, El-Tamer M. Omission of Radiotherapy After Breast-Conserving Surgery for Women With Breast Cancer With Low Clinical and Genomic Risk: 5-Year Outcomes of IDEA. Journal Of Clinical Oncology 2023, 42: 390-398. PMID: 38060195, DOI: 10.1200/jco.23.02270.Peer-Reviewed Original ResearchBreast-conserving surgeryIpsilateral breast eventsEndocrine therapyPostmenopausal patientsBreast cancerCrude rateLower riskBreast cancer-specific survival ratesUnifocal invasive breast cancersYears of ETCancer-specific survival ratesStage I breast cancerHuman epidermal growth factor receptor 2Epidermal growth factor receptor 2Omission of radiotherapyYounger postmenopausal patientsPatients age 50Primary end pointBreast conserving surgeryGrowth factor receptor 2I breast cancerInvasive breast cancerRecurrence 5 yearsPatients age 65Single-arm trial
2022
Radiation Therapy for Low-Risk Breast Cancer: Whole, Partial, or None?
Moran M, Ho A. Radiation Therapy for Low-Risk Breast Cancer: Whole, Partial, or None? Journal Of Clinical Oncology 2022, 40: 4166-4172. PMID: 36332170, DOI: 10.1200/jco.22.01751.Peer-Reviewed Original ResearchConceptsWide local excisionPartial breast irradiationBreast cancerRadiation therapyEstrogen receptor-positive/progesteroneLow-risk breast cancerOncology Grand Rounds seriesHuman epidermal growth factor receptor 2Left-sided breast cancerWhole breast radiation therapyEpidermal growth factor receptor 2Clinical-pathologic featuresPostmenopausal female patientsDose/fractionationGrowth factor receptor 2Sentinel node biopsyOmission of radiationCommon clinical scenariosFactor receptor 2Node biopsyPostoperative radiationLocal excisionFemale patientsBreast irradiationTreatment recommendations
2013
Is Ki-67 Expression Prognostic for Local Relapse in Early-Stage Breast Cancer Patients Treated With Breast Conservation Therapy (BCT)?
Hafeez F, Neboori HJ, Harigopal M, Wu H, Haffty BG, Yang Q, Schiff D, Moran MS. Is Ki-67 Expression Prognostic for Local Relapse in Early-Stage Breast Cancer Patients Treated With Breast Conservation Therapy (BCT)? International Journal Of Radiation Oncology • Biology • Physics 2013, 87: 344-348. PMID: 23910708, DOI: 10.1016/j.ijrobp.2013.05.052.Peer-Reviewed Original ResearchConceptsBreast conservation therapyEarly-stage breast cancer patientsHuman epidermal growth factor receptor 2Recurrence-free survivalBreast cancer patientsKi-67 expressionKi-67Clinicopathologic featuresConservation therapyCancer patientsIndependent associationLocoregional recurrence-free survivalDistant metastasis-free survivalLocal relapse-free survivalEpidermal growth factor receptor 2Univariate/multivariate analysisPrognostic clinicopathologic featuresCause-specific survivalHormone receptor statusGrowth factor receptor 2Metastasis-free survivalRelapse-free survivalKi-67 overexpressionSignificant independent associationKi-67 staining